Addex Therapeutics Ltd.
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
ADXN | SW
Overview
Corporate Details
- ISIN(s):
- CH0029850754 (+2 more)
- LEI:
- 89450068Y9KVP2MQGH86
- Country:
- Switzerland
- Address:
- c/o Addex Pharma SA, Chemin des Aulx 12, 1228 Plan-Les-Ouates
- Sector:
- Manufacturing
Description
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-11 01:00 |
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
|
English | 6.4 KB | ||
| 2025-12-04 01:00 |
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Co…
|
English | 15.4 KB | ||
| 2025-12-01 01:00 |
Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Con…
|
English | 6.0 KB | ||
| 2025-10-29 01:00 |
Addex Increases Issued Share Capital to Create Treasury Shares
|
English | 5.1 KB | ||
| 2025-09-30 02:00 |
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results …
|
English | 16.7 KB | ||
| 2025-09-26 02:00 |
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Result…
|
English | 5.8 KB | ||
| 2025-09-23 02:00 |
Addex Appoints Bank of New York Mellon as Depositary Bank
|
English | 4.7 KB | ||
| 2025-06-30 02:00 |
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine …
|
English | 7.3 KB | ||
| 2025-06-25 02:00 |
Addex Shareholders Approve All Resolutions at Annual General Meeting
|
English | 5.6 KB | ||
| 2025-06-19 02:00 |
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Upd…
|
English | 13.7 KB | ||
| 2025-06-18 02:00 |
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Cal…
|
English | 5.9 KB | ||
| 2025-06-06 02:00 |
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple…
|
English | 7.4 KB | ||
| 2025-06-05 02:00 |
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cou…
|
English | 6.4 KB | ||
| 2025-06-03 02:00 |
Addex Convenes Annual General Meeting 2025
|
English | 6.8 KB | ||
| 2025-05-12 02:00 |
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Suc…
|
English | 6.6 KB |
Automate Your Workflow. Get a real-time feed of all Addex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Addex Therapeutics Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Addex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-27 | N/A | Executive member | Buy | None | 301,345.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 53,760.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 45,450.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 44,856.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 24,423.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 5,487.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 3,927.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 2,150.00 CHF |
Peer Companies
